Finance entity

HEMANGEOL

Product

earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ASN-001, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.5.

Last mentioned: 3d ago

Entity pulse

Recent coverage · HEMANGEOL

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about HEMANGEOL

earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ASN-001, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.5. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. HEMANGEOL appears in 1 tracked Finance story from August 13, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering HEMANGEOL. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Jefferson Capital dividend payable

    Quarterly cash dividend of $0.24 per share is payable to shareholders.

  2. Jefferson Capital dividend record date

    Shareholders of record at close of business on August 24, 2026 qualify for the $0.24 per share dividend.

  3. Q2 2026 earnings releases

    Eton, Dawson, and Jefferson Capital report Q2 2026 financial results, with releases distributed at 20:30 UTC.

  4. Q2 2026 reporting period ends

    Eton Pharmaceuticals, Dawson Geophysical, and Jefferson Capital close the second quarter ended June 30, 2026.

  5. HEMANGEOL relaunch

    Eton relaunches HEMANGEOL in May 2026 with full Eton Cares patient support, including $0 copay for eligible patients.

Stories mentioning HEMANGEOL 1

Earnings Neutral

Q2 2026: Eton +99% Rev, Dawson +82%, Jefferson $0.24 Div

Three Q2 2026 earnings releases from Eton Pharmaceuticals, Dawson Geophysical, and Jefferson Capital show strong revenue growth but uneven profitability. Finance readers should focus on revenue catalysts, margin expansion, and dividend sustainability.

2 sources

HEMANGEOL is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.